Clinical Trials Logo

Recurrent Endometrial Cancer clinical trials

View clinical trials related to Recurrent Endometrial Cancer.

Filter by:

NCT ID: NCT06366347 Not yet recruiting - Endometrial Cancer Clinical Trials

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Start date: September 2024
Phase: Phase 2
Study type: Interventional

A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib and pembrolizumab alone following chemotherapy and pembrolizumab. The names of the study drugs involved in this study are: - Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) - Letrozole (a type of aromatase inhibitor) - Pembrolizumab (a type of monoclonal antibody)

NCT ID: NCT05798611 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART0380 in Patients With Biologically Selected Solid Tumors

ARTIST
Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

NCT ID: NCT05419817 Withdrawn - Solid Tumors Clinical Trials

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Start date: September 8, 2022
Phase: Phase 2
Study type: Interventional

This is a study of pembrolizumab in combination with sitravatinib in adult women with recurrent endometrial cancer or other solid tumors with deficient mismatch repair system. All patients enrolled will receive pembrolizumab as standard of care combined with Sitravatinib, which will be self-administered orally daily.

NCT ID: NCT05263492 Active, not recruiting - Endometrial Cancer Clinical Trials

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants

NCT ID: NCT04906382 Terminated - Lynch Syndrome Clinical Trials

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

NCT ID: NCT04197219 Withdrawn - Clinical trials for Recurrent Endometrial Cancer

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to see if adding the experimental medication, axitinib, to usual treatment with pembrolizumab will work better than pembrolizumab alone. The study team will look at overall safety and side effects of the combination of axitinib and pembrolizumab to see how well it is tolerated. Researchers will also want to take some research blood samples to explore what effects the combination of treatment has on participants' cells and immune system and to see if there are things in participants' blood that can predict a response or resistance to the combined treatment.

NCT ID: NCT03564340 Recruiting - Clinical trials for Recurrent Ovarian Cancer

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Start date: May 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to: - Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus - The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics - The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus - To find out how safe and tolerable the sarilumab pretreatment is, in combination with REGN4018 and cemiplimab

NCT ID: NCT03277482 Terminated - Clinical trials for Recurrent Ovarian Carcinoma

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: - Durvalumab - Tremelimumab

NCT ID: NCT02899793 Active, not recruiting - Clinical trials for Recurrent Endometrial Cancer

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Start date: September 2016
Phase: Phase 2
Study type: Interventional

Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer harboring an ultra-mutated or hyper-mutated (MMR gene-defective) phenotype identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP). To determine the nature and degree of toxicity of pembrolizumab as assessed by CTCAE in patients with persistent, recurrent or metastatic endometrial carcinoma. Secondary Objective(s): To estimate the duration of progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT02788708 Completed - Clinical trials for Primary Peritoneal Carcinoma

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Start date: May 27, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenvatinib mesylate when given together with paclitaxel in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer that has come back or grown. Lenvatinib mesylate may stop the growth of tumor cells by blocking a protein needed for cell growth and may block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenvatinib mesylate and paclitaxel together may work better in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.